Clinical Trials Sponsored by Shandong Suncadia Medicine Co., Ltd.

Total 1105 results

RenJi Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer Stage IV

China
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment

Breast Cancer

China
Fudan University
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer (PLEASURABLE)

Breast Cancer

China
Beijing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer

HER-2 Negatived Gastric Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Fudan University

Completed

Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer

Colorectal Cancer

China
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Hebei Medical University Fourth Hospital

Unknown

Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma

Non Hodgkin's Lymphoma

China
Wuxi Hisky Medical Technology Co Ltd
Qilu Hospital of Shandong University

Unknown

Effect of Dietary Interventions on Intestinal Flora and Metabolism

Dietary Interventions

China
Suzhou Genhouse Bio Co., Ltd.
Shanghai East Hospital; Shandong Tumor Hospital

Recruiting

A Phase I/II Clinical Study to Evaluate The Safety, PK, PD of GH55 in Patients With MAPK Mutant Advanced Solid Tumors

Advanced Solid Tumors With MAPK Signal Pathway Mutant

China
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Children's Hospital of Fudan University

Unknown

Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies

Lymphoma | Leukemia

China
Qu Yiqing
Qilu Pharmaceutical Co., Ltd.

Recruiting

Staphylococcus and Neisseria Tablets in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease.

Pulmonary Disease, Chronic Obstructive

China
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Peking University Cancer Hospital & Institute

Unknown

PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving Chemotherapy

Small Cell Lung Cancer | PEG-rhG-CSF

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)

Biliary Tract Cancer | Gemox Chemotherapy

China
Hubei Biological Medicine Industrial Technology...

Recruiting

A Study to Explore the Efficacy and Safety of HWH486 in Adults With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

China
Shanghai Unicar-Therapy Bio-medicine Technology...

Recruiting

Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Relapsed or Refractory Non-Hodgkin's Lymphoma

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer

HER2-positive Breast Cancer

China
Zhejiang Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC (WATCHER)

Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Breast Neoplasms

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Squamous Cell Carcinoma

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

China
Hubei Biological Medicine Industrial Technology...

Unknown

Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors

Advanced Solid Tumors | HRD | BRCA Mutation

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer

Small Cell Lung Cancer Extensive Stage

China
Harbin Medical University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC

HCC | NSCLC | CRC
Hebei Medical University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells

Gastric Cancer

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Treatment for Advanced Esophagus Cancer

Advanced Esophagus Cancer

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.

Osteosarcoma, Advanced

China
Jiangsu ShengDiYa Medicine Co., Ltd.
Dongguan People's Hospital

Unknown

Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC

Nonsquamous Nonsmall Cell Neoplasm of Lung
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer (NSCLC)

NSCLC
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast Cancer

Breast Cancer

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of Carilizumab Combined With Concurrent Chemoradiotherapy

Cervical Cancer
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer

Metastatic Breast Cancer

China
Shanghai Unicar-Therapy Bio-medicine Technology...

Recruiting

CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer

Small Cell Lung Cancer

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer

Colorectal Cancer

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

Soft Tissue Sarcoma | Uterine Cancer | Advanced Non Small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Hunan Cancer Hospital

Completed

Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects

Advanced Cancer

China
West China Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer

Breast Cancer | HER2 Positive | Combination Chemotherapy

China
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Chest Hospital

Unknown

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Chemotherapy Effect | KRAS Gene Mutation | NSCLC Stage IV | PD-1 Antibody
Beijing Chest Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer

Small Cell Lung Cancer
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
West China Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Apatinib in Recurrent or Recurrent High-grade Glioma

Glioma
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma

Malignant Melanoma

China
West China Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

Lung Cancer | Non Small Cell Lung Cancer | Apatinib | Combination Chemotherapy

China
Hebei Medical University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer

Gastric Cancer

China
Qingdao Municipal Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer

Gastric Cancer
Nanjing NingQi Medicine Science and Technology...

Unknown

Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research

Non-small Cell Lung Cancer

China
Nanjing NingQi Medicine Science and Technology...

Unknown

Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma

Advanced Lung Squamous Carcinoma

China
Sinovac Biotech Co., Ltd
Shandong Province Centers for Disease Control and Prevention

Completed

Immunogenicity and Safety of Two Different Commercial EV71 Vaccines

Hand, Foot and Mouth Disease

China
Shandong Cancer Hospital and Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients

Non Small Cell Lung Cancer

China
Shandong Cancer Hospital and Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Qilu Hospital of Shandong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer (ACDFNSNSCLC)

Non Small Cell Lung Cancer

Clinical Trials Sponsored by Shandong Suncadia Medicine Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations